Principal Investigator
David Kerman
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20211166
Clinical Trial Summary
A Randomized, Double-Blind, Placebo-Controlled, Phase 3
Trial of the Efficacy, Safety, and Tolerability of a Single Oral
Administration of CP101 for the Prevention of Recurrent
Clostridioides difficile Infection (PRISM4)
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Gastrointestinal, Stomach, Esophageal